{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:24:30Z","timestamp":1791854670568,"version":"4.3.4"},"reference-count":116,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.amepre.2017.12.022","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T08:04:05Z","timestamp":1526544245000},"page":"S230-S242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":227,"special_numbering":"S3","title":["Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment"],"prefix":"10.1016","volume":"54","author":[{"given":"Rebecca L.","family":"Haffajee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.B.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja A.","family":"Lagisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50\u201351","key":"10.1016\/j.amepre.2017.12.022_bib1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"50\u201351","key":"10.1016\/j.amepre.2017.12.022_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"10.1016\/j.amepre.2017.12.022_bib3","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers\u2013United States, 1999\u20132008","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"26","key":"10.1016\/j.amepre.2017.12.022_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugpo.2011.05.014","article-title":"Initiation into prescription opioid misuse amongst young injection drug users","volume":"23","author":"Lankenau","year":"2012","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.amepre.2017.12.022_bib6","article-title":"HHS Publication No. (SMA) 11-4658","year":"2014","journal-title":"Published"},{"issue":"7","key":"10.1016\/j.amepre.2017.12.022_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.amepre.2017.12.022_bib8","first-page":"1","article-title":"Associations of nonmedical pain reliever use and initiation of heroin use in the United States","author":"Muhuri","year":"2013","journal-title":"CBHSQ Data Rev"},{"issue":"1\u20132","key":"10.1016\/j.amepre.2017.12.022_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers\u2014United States, 2002\u20132004 and 2008\u20132010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amepre.2017.12.022_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1515195","article-title":"HIV infection linked to injection use of oxymorphone in Indiana, 2014\u20132015","volume":"375","author":"Peters","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib11","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"8","key":"10.1016\/j.amepre.2017.12.022_bib12","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/add.12536","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.amepre.2017.12.022_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/add.12860","article-title":"Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study","volume":"110","author":"Teesson","year":"2015","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.amepre.2017.12.022_bib14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.amepre.2017.12.022_bib16","first-page":"133","article-title":"HIV infection and HIV-associated behaviors among injecting drug users\u201320 cities, United States","volume":"61","author":"Spiller","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.amepre.2017.12.022_bib17","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2017.0001","article-title":"Opioid agonist treatment for patients with dependence on prescription opioids","volume":"317","author":"Nielsen","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amepre.2017.12.022_bib22","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib23","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amepre.2017.12.022_bib24","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.amepre.2017.12.022_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib26","unstructured":"The President\u2019s Commission on Combatting Drug Addiction and the Opioid Crisis. Final Report of The President\u2019s Commission on Combating Drug Addiction and the Opioid Crisis. www.whitehouse.gov\/sites\/whitehouse.gov\/files\/images\/Final_Report_Draft_11-1-2017.pdf. Published 2017."},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: the influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The untapped potential of office-based buprenorphine treatment","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamapsychiatry.2016.1390","article-title":"Use of opioid agonist therapy for Medicare patients in 2013","volume":"73","author":"Lembke","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"14","key":"10.1016\/j.amepre.2017.12.022_bib30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.amepre.2017.12.022_bib31","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib32","unstructured":"Medication-assisted treatment improves outcomes for patients with opioid use disorder. www.pewtrusts.org\/~\/media\/assets\/2016\/11\/medicationassistedtreatment_v3.pdf. Published 2016."},{"key":"10.1016\/j.amepre.2017.12.022_bib33","unstructured":"Title 21 United States Code (USC) Controlled Substances Act\u2014Section 801. www.deadiversion.usdoj.gov\/21cfr\/21usc\/801.htm. Accessed June 21, 2017."},{"key":"10.1016\/j.amepre.2017.12.022_bib34","unstructured":"Rinaldo SG, Rinaldo DW. Advancing access to addiction medication: implications for opioid addiction treatment. www.asam.org\/docs\/default-source\/advocacy\/aaam_implications-for-opioid-addiction-treatment_final. Published 2013."},{"key":"10.1016\/j.amepre.2017.12.022_bib35","unstructured":"42 CFR 8.12 Federal Opioid Treatment Standards. 2001:65-69. U.S. Government Publishing Office. www.gpo.gov\/fdsys\/granule\/CFR-2002-title42-vol1\/CFR-2002-title42-vol1-sec8-12."},{"key":"10.1016\/j.amepre.2017.12.022_bib36","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Opioid Treatment Program Directory. http:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx. Published 2017. Accessed June 28, 2017."},{"issue":"5","key":"10.1016\/j.amepre.2017.12.022_bib37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am J Public Health"},{"issue":"12","key":"10.1016\/j.amepre.2017.12.022_bib38","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"9810","key":"10.1016\/j.amepre.2017.12.022_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(11)61674-7","article-title":"Drug policy and the public good: evidence for effective interventions","volume":"379","author":"Strang","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"key":"10.1016\/j.amepre.2017.12.022_bib41","first-page":"CD011117","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","volume":"5","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amepre.2017.12.022_bib42","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib43","first-page":"1048","article-title":"Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up","volume":"6","author":"Metzger","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1377\/hlthaff.2015.0618","article-title":"Understanding patterns of high-cost health care use across different substance user groups","volume":"35","author":"Gryczynski","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.amepre.2017.12.022_bib45","doi-asserted-by":"crossref","first-page":"948789","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to opioid treatment programs in the United States","volume":"2011","author":"Rosenblum","year":"2011","journal-title":"J Environ Public Health"},{"issue":"14","key":"10.1016\/j.amepre.2017.12.022_bib46","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2014.2147","article-title":"Confronting the stigma of opioid use disorder\u2014and its treatment","volume":"311","author":"Olsen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.12.022_bib47","unstructured":"Facing Addiction in America: The Surgeon General\u2019s Report on Alcohol, Drugs, and Health. Washington, DC. https:\/\/addiction.surgeongeneral.gov\/surgeon-generals-report.pdf. Published 2016."},{"key":"10.1016\/j.amepre.2017.12.022_bib48","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.amepre.2017.12.022_bib50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"10118","key":"10.1016\/j.amepre.2017.12.022_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amepre.2017.12.022_bib52","unstructured":"Pew Charitable Trusts. The case for medication-assisted treatment. www.pewtrusts.org\/~\/media\/assets\/2017\/02\/thecasemedicationassistedtreatment.pdf. Published 2017."},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine\u2013naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib54","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib55","unstructured":"American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. https:\/\/www.asam.org\/docs\/default-source\/practice-support\/guidelines-and-consensus-docs\/asam-national-practice-guideline-supplement.pdf?sfvrsn=24. Published 2015."},{"issue":"10","key":"10.1016\/j.amepre.2017.12.022_bib56","doi-asserted-by":"crossref","first-page":"e0186315","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? a systematic review","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.amepre.2017.12.022_bib57","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.2016.10899","article-title":"Buprenorphine implants (Probuphine) for opioid dependence","volume":"316","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.12.022_bib58","unstructured":"Drugs.com. Probuphine dosage. www.drugs.com\/dosage\/probuphine.html. Published 2017. Accessed October 27, 2017."},{"key":"10.1016\/j.amepre.2017.12.022_bib59","unstructured":"Food and Drug Administration. Press release: FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm587312.htm. Published November 30, 2017."},{"key":"10.1016\/j.amepre.2017.12.022_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/pmt.12.26","article-title":"Buprenorphine for opioid addiction","volume":"2","author":"Ling","year":"2012","journal-title":"Pain Manag"},{"key":"10.1016\/j.amepre.2017.12.022_bib62","unstructured":"Hancock C, Mennenga H, King N, Andrilla H, Larson E, Schou P. National Rural Health Association Policy Brief: treating the rural opioid epidemic. www.ruralhealthweb.org\/NRHA\/media\/Emerge_NRHA\/Advocacy\/Policy%20documents\/Treating-the-Rural-Opioid-Epidemic_Feb-2017_NRHA-Policy-Paper.pdf. Published 2017."},{"issue":"6","key":"10.1016\/j.amepre.2017.12.022_bib63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.drugpo.2007.03.002","article-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia","volume":"19","author":"Winstock","year":"2008","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.amepre.2017.12.022_bib64","series-title":"Addicted to a treatment for addiction","author":"Macy","year":"2016"},{"key":"10.1016\/j.amepre.2017.12.022_bib65","series-title":"Addiction treatment with a dark side","author":"Sontag","year":"2016"},{"issue":"5","key":"10.1016\/j.amepre.2017.12.022_bib66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"J Addict Med"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib67","doi-asserted-by":"crossref","first-page":"335","DOI":"10.36076\/ppj.2005\/8\/335","article-title":"Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): a public law for balancing treatment of pain and drug abuse and diversion","volume":"8","author":"Manchikanti","year":"2005","journal-title":"Pain Physician"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib68","first-page":"377","article-title":"Just say no: the case against the reclassification of buprenorphine","volume":"12","author":"Sarpatwari","year":"2012","journal-title":"University of Maryland Law Journal of Race, Religion, Gender and Class"},{"issue":"3","key":"10.1016\/j.amepre.2017.12.022_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2017.12.022_bib70","unstructured":"106th U.S. Congress. Drug Addiction Treatment Act of 2000. www.gpo.gov\/fdsys\/pkg\/PLAW-106publ310\/pdf\/PLAW-106publ310.pdf."},{"key":"10.1016\/j.amepre.2017.12.022_bib71","unstructured":"109th U.S. Congress. Office of the National Drug Control Policy Reauthorization Act of 2006. www.congress.gov\/109\/plaws\/publ469\/PLAW-109publ469.pdf."},{"issue":"131","key":"10.1016\/j.amepre.2017.12.022_bib72","first-page":"44712","article-title":"Medication assisted treatment for opioid use disorders; final rule","volume":"81","year":"2016","journal-title":"Fed Regist"},{"key":"10.1016\/j.amepre.2017.12.022_bib73","unstructured":"114th U.S. Congress. Comprehensive Addiction and Recovery Act of 2016. www.gpo.gov\/fdsys\/pkg\/PLAW-114publ198\/pdf\/PLAW-114publ198.pdf."},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib74","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"11","key":"10.1016\/j.amepre.2017.12.022_bib75","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/jama.2016.10542","article-title":"Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment","volume":"316","author":"Stein","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of U.S. physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"issue":"5","key":"10.1016\/j.amepre.2017.12.022_bib77","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","article-title":"Unobserved versus observed office buprenorphine\/naloxone induction: a pilot randomized clinical trial","volume":"35","author":"Gunderson","year":"2010","journal-title":"Addict Behav"},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib78","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s11606-007-0264-7","article-title":"Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians","volume":"22","author":"Cunningham","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.amepre.2017.12.022_bib79","first-page":"336","article-title":"Attending physicians\u2019 and residents\u2019 attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital","volume":"38","author":"Cunningham","year":"2006","journal-title":"Fam Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib80","first-page":"3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians","volume":"15","author":"Deflavio","year":"2015","journal-title":"Rural Remote Health"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib81","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","article-title":"Integrating buprenorphine treatment into office-based practice: a qualitative study","volume":"24","author":"Barry","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychol Addict Behav"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1363461516660884","article-title":"Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America","volume":"53","author":"Mendoza","year":"2016","journal-title":"Transcult Psychiatry"},{"issue":"3","key":"10.1016\/j.amepre.2017.12.022_bib84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.amepre.2017.12.022_bib85","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1521-0391.2012.00335.x","article-title":"Steps physicians report taking to reduce diversion of buprenorphine","volume":"22","author":"Yang","year":"2013","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"10.1016\/j.amepre.2017.12.022_bib86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5055\/jom.2012.0093","article-title":"Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters","volume":"8","author":"Quest","year":"2012","journal-title":"J Opioid Manag"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","article-title":"Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence","volume":"25","author":"Kissin","year":"2006","journal-title":"J Addict Dis"},{"key":"10.1016\/j.amepre.2017.12.022_bib90","unstructured":"White WL. Long-term strategies to reduce the stigma attached to addiction, treatment, and recovery within the city of Philadelphia (with particular reference to medication-assisted treatment\/recovery). Philadelphia, PA; 2009. www.williamwhitepapers.com\/pr\/2009Stigma%26methadone.pdf."},{"issue":"17","key":"10.1016\/j.amepre.2017.12.022_bib91","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamainternmed.2013.9059","article-title":"Responses of state Medicaid programs to buprenorphine diversion","volume":"173","author":"Clark","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","article-title":"Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians","volume":"39","author":"Arfken","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.amepre.2017.12.022_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J465v27n03_06","article-title":"Evaluation of a combined online and in person training in the use of buprenorphine","volume":"27","author":"Gunderson","year":"2006","journal-title":"Subst Abus"},{"issue":"8","key":"10.1016\/j.amepre.2017.12.022_bib94","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence doesn\u2019t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"10.1016\/j.amepre.2017.12.022_bib95","first-page":"1964","article-title":"The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence","volume":"49","author":"Clark","year":"2014","journal-title":"Health Serv Res"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/08897077.2015.1080208","article-title":"Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013","volume":"37","author":"Burns","year":"2016","journal-title":"Subst Abus"},{"issue":"12","key":"10.1016\/j.amepre.2017.12.022_bib97","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1377\/hlthaff.2016.0623","article-title":"Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","author":"Grogan","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"20","key":"10.1016\/j.amepre.2017.12.022_bib98","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2016.3674","article-title":"A stronger treatment system for opioid use disorders","volume":"315","author":"Saloner","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2017.12.022_bib99","doi-asserted-by":"crossref","unstructured":"Maclean JC, Saloner B. The effect of public insurance expansions on substance use disorder treatment: evidence from the Affordable Care Act. NBER Working Paper No. 23342. www.nber.org\/papers\/w23342. Published 2017.","DOI":"10.3386\/w23342"},{"key":"10.1016\/j.amepre.2017.12.022_bib100","unstructured":"Beronio K, Po R, Skopec L, Glied S. ASPE research brief: Affordable Care Act expands mental health and substance use disorder benefits and federal parity protections for 62 million Americans. https:\/\/aspe.hhs.gov\/report\/affordable-care-act-expands-mental-health-and-substance-use-disorder-benefits-and-federal-parity-protections-62-million-americans. Published 2013. Accessed June 28, 2017."},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib101","first-page":"50","article-title":"How the Affordable Care Act and Mental Health Parity and Addiction Equity Act greatly expand coverage of behavioral health care","volume":"27","author":"Beronio","year":"2018","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib102","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hec.3482","article-title":"Access to health insurance and utilization of substance use disorder treatment: evidence from the Affordable Care Act dependent coverage provision","volume":"27","author":"Saloner","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.amepre.2017.12.022_bib103","series-title":"Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008","year":"2008"},{"issue":"21","key":"10.1016\/j.amepre.2017.12.022_bib104","first-page":"5410","article-title":"Interim Final Rules Under the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008","volume":"75","year":"2010","journal-title":"Fed Regist"},{"key":"10.1016\/j.amepre.2017.12.022_bib105","first-page":"68239","article-title":"Final Rules Under the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008","volume":"78","year":"2013"},{"key":"10.1016\/j.amepre.2017.12.022_bib106","unstructured":"The National Center on Additional and Substance Abuse. Uncovering coverage gaps: a review of addiction benefits in ACA plans. www.centeronaddiction.org\/addiction-research\/reports\/uncovering-coverage-gaps-review-of-addiction-benefits-in-aca-plans. Published 2016."},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib107","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ajad.12550","article-title":"Access to treatment for opioid use disorders: medical student preparation","volume":"26","author":"McCance-Katz","year":"2017","journal-title":"Am J Addict"},{"issue":"1","key":"10.1016\/j.amepre.2017.12.022_bib108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","article-title":"Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders.","volume":"37","author":"Komaromy","year":"2016","journal-title":"Subst Abus"},{"issue":"9","key":"10.1016\/j.amepre.2017.12.022_bib109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11606-010-1377-y","article-title":"The physician clinical support system-buprenorphine (PCSS-B): A novel project to expand\/improve buprenorphine treatment","volume":"25","author":"Egan","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib110","series-title":"Strengthening the Addiction Treatment Workforce Act","author":"Donnelly","year":"2017"},{"issue":"2","key":"10.1016\/j.amepre.2017.12.022_bib111","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.amepre.2017.12.022_bib112","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amepre.2017.12.022_bib113","unstructured":"Food and Drug Administration. Administering the Hatch-Waxman amendments: ensuring a balance between innovations and access: public meeting; request for comments. www.fda.gov\/Drugs\/NewsEvents\/ucm563986.htm. Published 2017."},{"key":"10.1016\/j.amepre.2017.12.022_bib114","unstructured":"The Mental Health and Substance Use Disorder Parity Task Force: Final Report. Washington, DC. www.hhs.gov\/sites\/default\/files\/mental-health-substance-use-disorder-parity-task-force-final-report.pdf. Published 2016."},{"key":"10.1016\/j.amepre.2017.12.022_bib115","series-title":"Upton F. 21st Century Cures Act","year":"2015"},{"key":"10.1016\/j.amepre.2017.12.022_bib116","series-title":"$45 billion to fight opioid abuse? That\u2019s much too little, experts say","author":"Goodnough","year":"2017"},{"key":"10.1016\/j.amepre.2017.12.022_bib117","unstructured":"Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, \u201cFederal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives.\u201d www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm582031.htm. Published 2017. Accessed October 25, 2017."}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718300746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379718300746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T20:51:21Z","timestamp":1661287881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379718300746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0749379718300746"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2017.12.022","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2017.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Journal of Preventive Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}